©2018 Immunicom, Inc. All rights reserved.

6048 CORNERSTONE COURT W

SUITE D, 

SAN DIEGO, CA 92121

  • Black LinkedIn Icon

Research

[Full discussion of] Immunicom’s Canine Comparative Oncology Clinical Trial solidly validates concept; Demonstrated measurable positive effects, safety, and tolerability; Facilitates transition to human clinical trials – EU, FDA, NIH compatibility

 

Strong Historical Perspective & Highly Translatable Clinical Trial Results Previously Conducted in Humans; extensive prior clinical assessments soundly establish role of TNF receptors (sTNFR) in Human Cancer Patients; sTNFR correlated with disease staging and shown to enhance tumor growth and persistence

Apheresis based treatments explored in Human Cancer Patients (see Appendix)

  1. Non-selective filtering of plasma & use of Polyclonal Rabbit Antibody apheresis produced clear beneficial clinical effects

  2. General improvements (physical condition, appetite, weight gain), successful reductions in tumor size, remissions/partial remissions realized

  3. BUT, these approaches had safety drawbacks due to Antibody technology, requirement of large volume plasma exchange and / or resulting in tumor lysis syndrome

 

Brief discussion of Upcoming Human Clinical Program

 

Full Listing of Relevant Publications